Abstract
Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.
Keywords: Autoimmune disease, glial activation, neuroinflammation, neurodegeneration, prolyl oligopeptidase, POP, Antigen presenting cells, Bradykinin, Renin-angiotensin system, Ac-SDKP, COPD, Bronchiolitis Obliterans Syndrome, Rheumatoid Arthritis, Mycobacterium tuberculosis, Systemic Lupus Erythematosus
CNS & Neurological Disorders - Drug Targets
Title: Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
Volume: 10 Issue: 3
Author(s): Anne Penttinen, Jofre Tenorio-Laranga, Anssi Siikanen, Markus Morawski, Steffen Roßner and J. Arturo Garcia-Horsman
Affiliation:
Keywords: Autoimmune disease, glial activation, neuroinflammation, neurodegeneration, prolyl oligopeptidase, POP, Antigen presenting cells, Bradykinin, Renin-angiotensin system, Ac-SDKP, COPD, Bronchiolitis Obliterans Syndrome, Rheumatoid Arthritis, Mycobacterium tuberculosis, Systemic Lupus Erythematosus
Abstract: Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.
Export Options
About this article
Cite this article as:
Penttinen Anne, Tenorio-Laranga Jofre, Siikanen Anssi, Morawski Markus, Roßner Steffen and Arturo Garcia-Horsman J., Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653742
DOI https://dx.doi.org/10.2174/187152711794653742 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Efficient Multiple Kernel Support Vector Regression Model for Assessing Dry Weight of Hemodialysis Patients
Current Bioinformatics Progress in the Discovery of Treatments for C. difficile Infection: A Clinical and Medicinal Chemistry Review
Current Topics in Medicinal Chemistry Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design Effects of Static Magnetic Fields on Blood Pressure in Animals and Humans
Current Hypertension Reviews Angiotensin, The Hormone to be Blocked by Antithypertensive Drugs, and Perhaps Why They Dont Work
Current Vascular Pharmacology Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Beta-Blockers and Nitrates: Pharmacotherapy and Indications
Cardiovascular & Hematological Agents in Medicinal Chemistry Bedside Cardiac Pocus in Emergency Setting: A Practice Review
Reviews on Recent Clinical Trials Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Central Nervous System Agents in Medicinal Chemistry Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews Fatal Disseminated Toxoplasmosis During Primary HIV Infection
Current HIV Research Sleep and Antidepressant Treatment
Current Pharmaceutical Design Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme
Current Pharmaceutical Design The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy
Current Pharmaceutical Biotechnology Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?
Current Pharmaceutical Design Interaction Between Bone and Muscle in Older Persons with Mobility Limitations
Current Pharmaceutical Design Molecular Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Hemodialysis Patients
Current Signal Transduction Therapy The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer
Anti-Cancer Agents in Medicinal Chemistry The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure
Current Topics in Medicinal Chemistry